Cargando…

Trimodal Therapy in Esophageal Squamous Cell Carcinoma: Role of Adjuvant Therapy Following Neoadjuvant Chemoradiation and Surgery

SIMPLE SUMMARY: In this work, we aimed to explore the effectiveness of adjuvant therapy after trimodal therapy (neoadjuvant chemoradiotherapy and esophagectomy) in patients with thoracic esophageal squamous cell carcinoma (ESCC). Overall survival (OS) and disease-free survival (DFS) were both compar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaokun, Luan, Siyuan, Yang, Yushang, Zhou, Jianfeng, Shang, Qixin, Fang, Pinhao, Xiao, Xin, Zhang, Hanlu, Yuan, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367572/ https://www.ncbi.nlm.nih.gov/pubmed/35954385 http://dx.doi.org/10.3390/cancers14153721

Ejemplares similares

The impact of geriatric nutritional risk index on esophageal squamous cell carcinoma patients with neoadjuvant therapy followed by esophagectomy
por: Fang, Pinhao, et al.
Publicado: (2022)

Prognostic value of micro-RNA 375, 133, 143, 145 in esophageal carcinoma: A systematic review and meta-analysis
por: Fang, Pinhao, et al.
Publicado: (2022)

Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications
por: Fang, Pinhao, et al.
Publicado: (2022)

Prognostic Value of Geriatric Nutritional Risk Index in Esophageal Carcinoma: A Systematic Review and Meta-Analysis
por: Zhou, Jianfeng, et al.
Publicado: (2022)

The prognostic value of sarcopenia in oesophageal cancer: A systematic review and meta‐analysis
por: Fang, Pinhao, et al.
Publicado: (2022)

Trimodality Therapy vs Definitive Chemoradiation in Older Adults With Locally Advanced Esophageal Cancer
por: Gaber, Charles E, et al.
Publicado: (2022)

Predictive value of preoperative weight loss on survival of elderly patients undergoing surgery for esophageal squamous cell carcinoma
por: Zhang, Hanlu, et al.
Publicado: (2019)

Trimodal therapy in squamous cell carcinoma of the esophagus
por: Matuschek, C, et al.
Publicado: (2011)

Commentary: Adjuvant chemotherapy after trimodal therapy for esophageal carcinoma: A bitter pill to swallow
por: Du, Valerie X., et al.
Publicado: (2020)

Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients
por: FUJIWARA, YOSHINORI, et al.
Publicado: (2012)

Prognostic significance of lymph node ratio after neoadjuvant chemoradiation therapy for esophageal squamous cell carcinoma
por: Jang, Jeong Yun, et al.
Publicado: (2020)

Neoadjuvant and adjuvant therapy in esophageal cancer
por: Weiss, Jennifer A., et al.
Publicado: (2023)

Clinical significance of risk stratification of esophageal squamous cell carcinoma after neoadjuvant chemoradiation and surgery
por: Wu, Ya-hua, et al.
Publicado: (2021)

Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols
por: Li, Chia-Ying, et al.
Publicado: (2016)

Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer
por: Mohammed, Ayatallah Ali Youssief, et al.
Publicado: (2023)

Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer
por: Vyfhuis, Melissa A.L., et al.
Publicado: (2017)

Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics
por: Yang, Yushang, et al.
Publicado: (2023)

Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma
por: So, Tsz Him, et al.
Publicado: (2020)

Correlation between TXNRD1/HO-1 expression and response to neoadjuvant chemoradiation therapy in patients with esophageal squamous cell carcinoma
por: Akaishi, Ryujiro, et al.
Publicado: (2022)

Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
por: Cheng, Jiahan, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series
por: Hadzitheodorou, Christina, et al.
Publicado: (2017)

Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer
por: Mao, Chengyi, et al.
Publicado: (2021)

Upfront surgery and pathological stage-based adjuvant chemoradiation strategy in locally advanced esophageal squamous cell carcinoma
por: Chen, Hui-Shan, et al.
Publicado: (2018)

HO‐1 in lymph node metastasis predicted overall survival in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiation therapy
por: Akaishi, Ryujiro, et al.
Publicado: (2021)

Prognostic significance of tumor regression grade in esophageal squamous cell carcinoma after neoadjuvant chemoradiation
por: Zhang, Chi, et al.
Publicado: (2023)

Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma
por: Goense, Lucas, et al.
Publicado: (2018)

Radiation dose mapping and anastomotic complications after trimodality therapy for esophageal cancers
por: Bang, Andrew, et al.
Publicado: (2019)

Risk stratification of postoperative cardiopulmonary toxicity after trimodality therapy for esophageal cancer
por: Kowalchuk, Roman O., et al.
Publicado: (2023)

Adjuvant Therapy for Esophageal Squamous Cell Carcinoma
por: Sun, Jong-Mu
Publicado: (2020)

Lymph Node Status after Neoadjuvant Chemoradiation Therapy for Esophageal Cancer according to Radiation Field Coverage
por: Kim, Sang Yoon, et al.
Publicado: (2019)

Role of FDG-PET/CT in prediction of pathological tumor response and survival after trimodality therapy for esophageal squamous cell carcinoma
por: Hamai, Yoichi, et al.
Publicado: (2015)

Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma
por: Tamotsu, Kiyokazu, et al.
Publicado: (2015)

ASO Author Reflections: Predicting Early Recurrence After Trimodality Therapy for Esophageal Adenocarcinoma
por: Goense, Lucas, et al.
Publicado: (2018)

Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients
por: Warnecke-Eberz, Ute, et al.
Publicado: (2020)

Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
por: Matani, Hirsch, et al.
Publicado: (2022)

Trimodal Therapy: A Tumor Vascular‐Targeted Interlocking Trimodal Nanosystem That Induces and Exploits Hypoxia (Adv. Sci. 8/2018)
por: Luan, Xin, et al.
Publicado: (2018)

Optimal timing of surgery after neoadjuvant chemoradiation therapy in locally advanced rectal cancer
por: Jeong, Duck Hyoun, et al.
Publicado: (2013)

Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy
por: Nevala-Plagemann, Christopher, et al.
Publicado: (2018)

Time to Surgery for Patients with Esophageal Cancer Undergoing Trimodal Therapy in Ontario: A Population-Based Cross-Sectional Study
por: Hanna, Nader M., et al.
Publicado: (2022)

Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancer
por: Rizzo, Alessandro
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1u1q6s1248f9jcjr8sh96j8huj